GLC Medical (GLCM) Inc. is pleased to announce the signing of a Memorandum
of Understanding (MoU) with a very significant UAE company with the intent to advance the GLCM Biosensor Platform to commercialization.
The UAE partner is invested in multiple sectors with strategic partnerships dedicated to innovation, excellence and integrity aimed at futuristic technologies, and has strong ties with the UAE government in their technological advancement goals.
The MoU signing took place in Dubai, UAE on Wednesday, February 1, 2023. The MoU represents a mutual commitment to advance the GLCM Biosensor Platform into market. GLCM will undertake a series of testing in Dubai and area in March 2023, with our partner managing regulatory and global distribution opportunities. A global license and purchase orders will enable GLCM and partner to ensure logistics are in place for a future full scale-up strategy. This partnership brings together expertise in innovative technology solutions with GLCM’s expertise in the Biosensor Platform. The result is an innovative platform that will change the way pathogen testing is done, making it faster, more efficient, and accessible to a global audience.